Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida. Show more

501 E. Las Olas Blvd., Fort Lauderdale, FL, 33301, United States

Biotechnology
Healthcare

Market Cap

6.054M

52 Wk Range

$1.67 - $6.20

Previous Close

$2.52

Open

$2.56

Volume

8,466

Day Range

$2.47 - $2.56

Enterprise Value

4.813M

Cash

1.385M

Avg Qtr Burn

-552K

Insider Ownership

14.11%

Institutional Own.

5.97%

Qtr Updated

12/31/25